The Next Step of Their Control Is Here …

Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.

4 simple steps to protect your privacy and money before it’s too late.

Sasha King Biography and Net Worth

CMO of CareDx

Sasha King brings over 10 years of diagnostics and genetic testing experience. Most recently she worked in companion diagnostics marketing at Genentech, and was a sales leader at Ariosa Diagnostics. While at Genentech, she worked on the launch of the first FDA approved cell free DNA test in oncology, the PD-L1 test launch, and the Foundation Medicine partnership. Sasha was an early member of the commercial team at Ariosa, a leader in the field of noninvasive prenatal testing (NIPT) which is now part of the Roche Group. She led the launch of their test into Asia Pacific and Canada. Sasha previously worked at Fletcher Spaght, a life science consulting and venture capital fund. Sasha received a bachelor of science in bioengineering from Massachusetts Institute of Technology and an MBA from Stanford Graduate School of Business.

What is Sasha King's net worth?: The estimated net worth of Sasha King is at least $362,222.28 as of June 9th, 2021. Ms. King owns 47,913 shares of CareDx stock worth more than $362,222 as of April 26th. This net worth approximation does not reflect any other assets that Ms. King may own. Learn More about Sasha King's net worth.
How do I contact Sasha King?: The corporate mailing address for Ms. King and other CareDx executives is 1 TOWER PLACE 9TH FLOOR, SOUTH SAN FRANCISCO CA, 94080. CareDx can also be reached via phone at (415) 287-2300 and via email at [email protected]. Learn More on Sasha King's contact information.
Has Sasha King been buying or selling shares of CareDx?: Sasha King has not been actively trading shares of CareDx within the last three months. Most recently, Sasha King sold 12,435 shares of the business's stock in a transaction on Wednesday, June 9th. The shares were sold at an average price of $90.01, for a transaction totalling $1,119,274.35. Following the completion of the sale, the chief marketing officer now directly owns 47,913 shares of the company's stock, valued at $4,312,649.13. Learn More on Sasha King's trading history.
Who are CareDx's active insiders?: CareDx's insider roster includes Paul Adler (CEO), George Bickerstaff, III (Director), Ankur Dhingra (CFO), Michael Goldberg (Director), William Hagstrom (Director), Sasha King (CMO), Peter Maag (Insider), Reginald Seeto (Insider), Ralph Snyderman (Director), and Thomas Thomas (Director). Learn More on CareDx's active insiders.
Are insiders buying or selling shares of CareDx?: In the last twelve months, insiders at the sold shares 11 times. They sold a total of 44,448 shares worth more than $405,276.89. The most recent insider tranaction occured on October, 2nd when insider Reginald Seeto sold 2,818 shares worth more than $19,472.38. Insiders at CareDx own 4.2% of the company. Learn More about insider trades at CareDx.
Information on this page was last updated on 10/2/2023.

Sasha King Insider Trading History at CareDx

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/9/2021	Sell	12,435	$90.01	$1,119,274.35	47,913
6/7/2021	Sell	8,071	$90.01	$726,470.71	50,567
1/14/2021	Sell	9,875	$87.55	$864,556.25	44,264
10/8/2020	Sell	40,775	$50.62	$2,064,030.50	61,760
6/1/2020	Sell	25,402	$33.10	$840,806.20	28,334
2/14/2020	Sell	7,390	$26.01	$192,213.90	48,502
12/9/2019	Sell	2,126	$21.97	$46,708.22	48,709
7/1/2019	Sell	9,542	$35.74	$341,031.08	62,045
6/20/2019	Sell	30,840	$38.38	$1,183,639.20	72,772
5/3/2019	Sell	1,250	$29.50	$36,875.00	77,427
4/12/2019	Sell	10,000	$29.81	$298,100.00	75,137
2/22/2019	Sell	7,500	$29.03	$217,725.00	81,387
2/15/2019	Sell	2,500	$25.00	$62,500.00	76,387
10/5/2018	Sell	11,500	$24.60	$282,900.00	53,542
8/1/2018	Sell	9,458	$14.03	$132,695.74	71,792

Sasha King Buying and Selling Activity at CareDx

CareDx Company Overview

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Today's Range

Now: $7.56

$7.42

$7.84

50 Day Range

MA: $9.62

$7.56

$12.08

2 Week Range

Now: $7.56

$4.80

$12.93

Volume

492,964 shs

Average Volume

888,127 shs

Market Capitalization

$391.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.42